Article Text

Opinion
Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense?
  1. Vanessa M McDonald1,2,3,
  2. Isabel Higgins1,
  3. Lisa G Wood3,4,
  4. Peter G Gibson2,4,5
  1. 1School of Nursing and Midwifery, University of Newcastle, Newcastle, New South Wales, Australia
  2. 2School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia
  3. 3Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, New Lambton, New South Wales, Australia
  4. 4School of Biomedical Science, University of Newcastle, Newcastle, New South Wales, Australia
  5. 5Woolcock Institute of Medical Research, Sydney, New South Wales, Australia
  1. Correspondence to Peter G Gibson, Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, Locked Bag #1000, New Lambton, NSW 2305, Australia; peter.gibson{at}hnehealth.nsw.gov.au

Abstract

Introduction The rising disease burden from chronic obstructive pulmonary disease (COPD) requires new approaches.

Method We suggest an approach based around three elements: inflammometry and multidimensional assessment to identify therapeutic targets and case management to design and implement an individualised treatment programme based on these assessments.

Discussion This tailored approach to treatment would maximise efficacy, limit cost and permit a better risk–benefit ratio of treatment. The advantages include the ability to add up the benefits of individual therapies leading to a cumulative therapeutic benefit that is greater than each individual therapy alone. We can now design a multifaceted inflammometry intervention for airway diseases based on targeting eosinophilic inflammation, non-eosinophilic pathways and systemic inflammation. COPD is a complex and challenging disease. The use of inflammometry and multidimensional assessment is necessary to identify relevant treatment targets and maximise the scope of therapy while limiting unnecessary use of drugs. An individualised programme of management can be designed and coordinated by using a case manager. This new approach may provide tangible benefits to people with COPD.

  • COPD Pharmacology
  • Systemic disease and lungs

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Linked Articles